Viking Therapeutics has delivered a very large 463.7% return over the past five years, yet the stock currently screens as expensive on the valuation checks, which raises questions about how much optimism is already in the price.

• Over five years, Viking Therapeutics has returned 463.7%, which signals investors have already paid up heavily for the growth story.
• Expectations for future revenue and cash flow from Viking Therapeutics' pipeline can support a premium, although any delay in turning that potential into sustained cash generation may weigh on what investors are willing to pay.
• The company passes 0 of 6 valuation checks, which suggests Viking Therapeutics does not look like a clear bargain on Simply Wall St's broader tests of value at the moment, as shown by its 0 out of 6 valuation score.

The issue now is whether Viking Therapeutics' current share price still offers an appealing entry point after such a strong multi year run, or whether investors are paying too much for the story already priced into the stock.

Does Viking Therapeutics Look Pricey on Book Value?

The price to book ratio is often a useful cross check for Viking Therapeutics because it is still working toward meaningful revenue and earnings. On this measure, Viking Therapeutics trades at a P/B of 9.5x, which is roughly double the peer average of 4.8x and well above the broader biotech industry average of 2.5x. That suggests investors are paying a high price for each dollar of net assets on the balance sheet.

The valuation model here also flags a large gap between this trading multiple and what it would expect for a company with Viking Therapeutics' current losses and risk profile. The model is heavily penalising the lack of positive free cash flow and is better read as a warning signal that the stock appears very fully priced on this framework rather than a precise fair value estimate.

On the P/B multiple, Viking Therapeutics stock currently appears expensive compared with both peers and the wider biotech sector.

The Viking Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Viking Therapeutics valuation puzzle leaves off and explain what kind of future growth, margins and earnings would need to occur for the stock to be worth materially more or materially less than today’s price.

Each narrative sets out the assumptions that underpin its view of fair value, so you can compare those expectations with Viking Therapeutics' actual results as they are reported, and they are available on the company’s Community page on Simply Wall St.

One of the top community narratives on Viking Therapeutics: 73% undervalued

"The oral VK2735 program, supported by Phase II data with double digit weight loss percentages and plans to move into Phase III, gives Viking a second high value product path..."

Do you think there's more to the story for Viking Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For Viking Therapeutics, the current picture points to an overvalued stock on the market-multiple view, with a very wide gap to peers on metrics like P/B. That does not rule out further upside; however, it does mean expectations already build in a lot of success from the pipeline. The crux for investors is whether future clinical and commercial progress arrives quickly and cleanly enough to support that premium, or whether sentiment cools and the multiple resets closer to the sector.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.